(Q34071798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

review article

1 reference

title

Has the outlook improved for amifostine as a clinical radioprotector? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

J C Lindegaard

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy and Oncology

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

113-118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Tumor blood flow changes induced by chemical modifiers of radiation response

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection of mouse skin by WR-2721: The critical influence of oxygen tension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Is the outlook grey for WR-2721 as a clinical radioprotector?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection by WR-2721 in vitro at low oxygen tensions: Implications for its mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radiosensitisation and radioprotection by BSO and WR-2721: the role of oxygenation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Use of radiation with or without WR-2721 in advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Effect of Radioprotective Drugs on the Therapeutic Ratio for a Mouse Tumor System

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Influence of WR 2721 on radiation response of canine soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Protective effects of WR-2721 against radiation-induced injury of murine gut, testis, lung, and lung tumor nodules

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Dephosphorylation of WR-2721 with mouse tissue homogenates

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Cysteine Protection against X Irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Protection of Normal Tissues from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine (WR-2721): Preclinical Aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection of tumor and normal tissues by thiophosphate compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radioprotection of Normal Tissues against Gamma Rays and Cyclotron Neutrons with WR-2721: LD 50 Studies and 35 S-WR-2721 Biodistribution

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

The influence of X ray dose levels on normal tissue radioprotection by WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Experimental radiotherapy with WR-2721 and misonidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Interaction of misonidazole and WR-2721—II. Modification of tumour radiosensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Fractionation studies with WR-2721: normal tissues and tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

The Effect of S-2-(3-Aminopropylamino)ethylphosphorothioic Acid (WR-2721) on Intestinal Crypt Survival: II. Fission Neutrons

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Target cell and mode of radiation injury in rhesus salivary glands

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radiation apoptosis of serous acinar cells of salivary and lacrimal glands.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

The oxygen dependence of protection by aminothiols: Implications for normal tissues and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Differential radioprotection of euoxic and hypoxic mouse mammary tumors by a thiophosphate compound.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Prediction of the Effective Radioprotective Dose of WR-2721 in Humans through an Interspecies Tissue Distribution Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Tumor sensitization and protection: Influence of stromal injury on estimates of dose modification

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Protective drugs in cancer therapy: Optimal clinical testing and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Efficacy testing of WR-2721 in Great Britain or everything is black and white at the gray lab

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Combined Use of Radioprotective and Radiosensitizing Drugs in Experimental Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

Variation in normal tissue responsiveness to WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2800%2900235-8

7 January 2021

10.1016/S0167-8140(00)00235-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11054513%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference